Mui Chi Hung Replaces Tam Man Kin as CFO of China Regenerative Medicine

Tam Man Kin has resigned as Chief Financial Officer of China Regenerative Medicine International Limited effective September 14, 2016. Replacing Tam is Mui Chi Hung.

Mui, aged 50, has over 20 years of experience in nancing, auditing and accounting. Prior to joining the company, Mui held various senior positions in a few listed groups and international accounting firm, including PricewaterhouseCoopers, Lansen Pharmaceutical Holdings Limited, China Smarter Energy Group Holdings Limited and Legend Strategy International Holdings Group Company Limited.

Mui spent 7 years serving as the Financial Controller, Company Secretary and Executive Director in Rising and 5 years serving as the CFO and Company Secretary in Lansen. 

Suggested Articles

Some of you might have already been aware of the news that Questex—with the aim to focus on event business—will shut down permanently all media brands in Asia…

Some advice for transitioning into an advisory role

Global risks are intensifying but the collective will to tackle them appears to be lacking. Check out this report for areas of concern